BR112013029617A2 - métodos para melhorar e gerenciar tratamento baseado na inibição de transcriptase reversa de nucleosídeo - Google Patents

métodos para melhorar e gerenciar tratamento baseado na inibição de transcriptase reversa de nucleosídeo

Info

Publication number
BR112013029617A2
BR112013029617A2 BR112013029617A BR112013029617A BR112013029617A2 BR 112013029617 A2 BR112013029617 A2 BR 112013029617A2 BR 112013029617 A BR112013029617 A BR 112013029617A BR 112013029617 A BR112013029617 A BR 112013029617A BR 112013029617 A2 BR112013029617 A2 BR 112013029617A2
Authority
BR
Brazil
Prior art keywords
reverse transcriptase
nucleic acid
acid sequence
methods
reverse
Prior art date
Application number
BR112013029617A
Other languages
English (en)
Inventor
Perrin-East Christèle
Gluschankof Pablo
Original Assignee
Amikana Biologics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amikana Biologics filed Critical Amikana Biologics
Publication of BR112013029617A2 publication Critical patent/BR112013029617A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01074—Deoxycytidine kinase (2.7.1.74)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01019—Imidazoleglycerol-phosphate dehydratase (4.2.1.19)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

abstract methods for improving and managing nucleoside reverse-transcriptase inhibition based treatment the present invention relates to a transformed yeast cell comprising: * a nucleic acid sequence coding for a reverse transcriptase, * a reverse transcription indicator, * a nucleic acid sequence coding for deoxycytidine kinase (dck), and * at least one nucleic acid sequence coding for nucleoside transporter; and to its uses in methods for screening a compound with the ability to inhibit reverse transcription and for predicting the sensitivity of a reverse transcriptase to a nrti compound, particularly a reverse transcriptase derived from a virus infecting a subject. tradução do resumo resumo pedido de patente: "métodos para melhorar e gerenciar tratamento baseado na inibição de transcriptase reversa de nucleosídeo". a presente invenção refere-se a uma célula de levedura transformada compreendendo: - uma sequência de ácido nucléico codificando por uma transcriptase reversa, - um indicador de transcrição reversa, - uma sequência de ácido nucléico codificando por deoxicitidina cinase (dck), e - pelo menos uma sequência de ácido nucléico codificando por transportador de nucleosídeo; e por seus usos em métodos por varredura de um composto com a capacidade de inibir transcrição reversa por prever a sensibilidade de uma transcriptase reversa por um composto de nrti, particularmente uma transcriptase reversa derivada de um vírus infectando um sujeito.
BR112013029617A 2011-05-17 2012-05-16 métodos para melhorar e gerenciar tratamento baseado na inibição de transcriptase reversa de nucleosídeo BR112013029617A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11004055 2011-05-17
PCT/EP2012/002107 WO2012156086A1 (en) 2011-05-17 2012-05-16 Methods for improving and managing nucleoside reverse-transcriptase inhibition based treatment

Publications (1)

Publication Number Publication Date
BR112013029617A2 true BR112013029617A2 (pt) 2017-06-13

Family

ID=46262070

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013029617A BR112013029617A2 (pt) 2011-05-17 2012-05-16 métodos para melhorar e gerenciar tratamento baseado na inibição de transcriptase reversa de nucleosídeo

Country Status (5)

Country Link
US (1) US9334524B2 (pt)
EP (1) EP2710125B1 (pt)
JP (1) JP2014519321A (pt)
BR (1) BR112013029617A2 (pt)
WO (1) WO2012156086A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3088535A1 (en) * 2015-04-29 2016-11-02 Amikana. Biologics Faculté de Médecine de la Timone Methods for identifying antiretroviral compounds targeting the reverse transcriptase of hiv

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462873A (en) 1991-03-13 1995-10-31 The United States Of America As Represented By The Department Of Health And Human Services DNA for use in a simple method for detecting inhibitors of retrotransposition
US5714313A (en) 1991-03-13 1998-02-03 United States Of America As Represented By The Department Of Health And Human Services Simple method for detecting inhibitors of retroviral replication
US6139569A (en) 1998-07-31 2000-10-31 Surx, Inc. Interspersed heating/cooling to shrink tissues for incontinence

Also Published As

Publication number Publication date
EP2710125B1 (en) 2016-03-23
US9334524B2 (en) 2016-05-10
EP2710125A1 (en) 2014-03-26
JP2014519321A (ja) 2014-08-14
WO2012156086A1 (en) 2012-11-22
US20140141461A1 (en) 2014-05-22

Similar Documents

Publication Publication Date Title
CL2012003381A1 (es) Compuestos derivados de 4-amino-3-fenil-1h-pirazolo[3,4-d]pirimidina; y compuesto (r)-1-(3-(4-amino-3-(4-fenoxifenil)-1h-pirazolo[3,4-d]pirimidin-1-il)piperidin-1-il)prop-2-en-1-ona para tratar el linfoma no hodgkin recurrente o resistente al tratamiento en un individuo; y uso de combinaciones con un segundo medicamento para el cancer.
Tan et al. The comparative genomics of human respiratory syncytial virus subgroups A and B: genetic variability and molecular evolutionary dynamics
BR112013029959A8 (pt) Anticorpos anti-cgrp e anti-cgrpr e seu uso para prevenir ou inibir fotofobia ou aversão à luz, composição farmacêutica compreendendo os referidos anticorpos, bem como sequência de ácido nucleico e célula recombinante
BR112014015152A2 (pt) métodos e materiais para a avaliação da perda de heterozigosidade
CL2014001562A1 (es) Compuestos derivados nucleosidos de purina y pirimidina, inhibidores de la replicacion del arn del vhc; composicion farmaceutica; y su uso para el tratamiento y profilaxis de la infeccion por el virus de la hepatitis c (vhc).
BR112013021986A2 (pt) "derivados de fosforamidato de 5-fluoro-2'-desoxiuridina, seus usos e seu processo de preparação, composição farmacêutica e método para sua preparação"
BR112012028805A2 (pt) composições de endorribonuclease e métodos de uso das mesmas.
JP2011037847A5 (pt)
AR062482A1 (es) Identificacion y caracterizacion de variantes de replicon de vhc con menor suceptibilidad a vhc 796, y metodos relacionados
NZ621733A (en) Lung cancer biomarkers and uses thereof
BRPI0821034A8 (pt) Vírus influenza b recombinante, seu uso, metodo de preparação, composição de vacina o contendo e seu gene m, bem como ácido nucléico isolado, molécula do vírus influenza m e seu uso e método para aumentar a taxa de crescimento de vírus influenza b deficiente de replicação
DK2718293T3 (da) Substituerede pyridopyraziner som hidtil ukendte syk-inhibitorer
BR112017025459A2 (pt) composição, método para tratamento de doença falciforme, kit, método para detecção de polissulfato pentosano de sódio (pps)
WO2010115745A3 (en) Biomarkers, methods and kits for the diagnosis of rheumatoid arthritis
BR112017014116A2 (pt) pcr quantitativo multiplex
BR112014015779A2 (pt) placa de aço espessa de alta resistência para uso estrutural com excelente capacidade de captura de rachadura frágil e método para produzir a mesma
BR112012019902A2 (pt) "método e compostos para o crescimento muscular"
BR112015021586A2 (pt) formulações de morfina
AR087363A1 (es) Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
BR112015013260A2 (pt) uso de inibidores de telomerase para o tratamento de distúrbios mieloproliferativos e neoplasias mieloproliferativas
BR112013029617A2 (pt) métodos para melhorar e gerenciar tratamento baseado na inibição de transcriptase reversa de nucleosídeo
WO2009152430A3 (en) Methods of treatment of bipolar disorder
Liang et al. Relations between stress life events and suicide ideation: Attributional style and help-seeking as moderators?
Gard et al. Assessing the structure and specificity of polygenic scores for psychiatric disorders in a population-based cohort of older adults
Williams et al. BCR–ABL and CDKN2A: a dropped connection

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]